Alzheimer’s drug has experts divided; rising ...

Australia has many stories from people who say they have long COVID but who are unable to access help | Updated versions of coronavirus vaccines targeting the Omicron variant have been announced, yet the virus still mutates | People with Type 1 diabetes need to monitor their bloo ...  Show more

What an Australian Centre for Disease Control might aim to be; An Indigenous perspective and research to engage culture for protection against cardiovascular disease and stroke; Research on links between mental health and mortality concludes that both mental and physical health c ...  Show more

The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it. For ...  Show more

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ...  Show more

When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.

But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ...

We begin with a discussion about our article of the week which comes from The Lancet and is entitled “Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-c ...